Pharmaceutical Cocrystals and Their Physicochemical Properties
By Nathan C. Schultheiss, A. Newman. Crystal Growth & Design, 2009
1,399 citations recorded by the source corpus.
Over the last 20 years, the number of publications outlining the advances in design strategies, growing techniques, and characterization of cocrystals has continued to increase significantly within the crystal engineering field. However, only within the last decade have cocrystals found their place in pharmaceuticals, primarily due to their ability to alter physicochemical properties without compromising the structural integrity of the active pharmaceutical ingredient (API) and thus, possibly, the bioactivity. This review article will highlight and discuss the advances made over the last 10 years pertaining to physical and chemical property improvements through pharmaceutical cocrystalline materials and, hopefully, draw closer the fields of crystal engineering and pharmaceutical sciences.
Subfields: Inorganic Chemistry, Materials Chemistry, Physical and Theoretical Chemistry
View Paper: https://www.semanticscholar.org/paper/7793ac75dbbc1281120db4857d6b1f99cf8b0ef9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Materials Chemistry
- Christopher J. H. Porter
- W. Charman
- S. Charman
- H. Williams
- R. Shanker
- Natalie L. Trevaskis
- Colin W. Pouton
Citations in the corpus
- Strategies to Address Low Drug Solubility in Discovery and Development (2013, background): “In these instances, drug concentrations in solution resulting from dissolution of the cocrystal will be in excess of the solubility of the thermodynamically stable drug crystal (Nehm et al., 2006; Good and Rodríguez-Hornedo, 2009; Schultheiss and Newman, 2009).”